The long-term impact of ferritin level on treatment and complications of type 2 diabetes

被引:2
作者
Jiang, L. [1 ]
Wang, A. [2 ]
Molyneaux, L. M. [3 ,4 ,5 ]
Constantino, M. I. [3 ,4 ]
Yue, D. K. [3 ,4 ,5 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] 306 Hosp, Ctr Diabet, Beijing, Peoples R China
[3] Royal Prince Alfred Hosp, Ctr Diabet, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Dept Endocrinol, Sydney, NSW, Australia
[5] Univ Sydney, Discipline Med, Sydney, NSW 2006, Australia
关键词
complications; ferritin; inflammation; insulin resistance; metabolic syndrome;
D O I
10.1111/j.1463-1326.2008.00855.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To investigate if high-serum ferritin has long-term impact on response to treatment and the development of diabetic complications in patients with type 2 diabetes. Research design and methods: We analysed the record of 90 consecutive type 2 diabetic subjects who had serum ferritin level determined soon after diagnosis of diabetes and who also had long-term follow-up data. Results: Patients with higher serum ferritin level had slightly worse triglyceride, blood pressure and liver enzyme levels at the end of follow up. However, ferritin level had no impact on the initial or final requirements for diabetic medication and the development of diabetic complications. Conclusions: Although elevated serum ferritin is a marker of insulin resistance and chronic inflammation, it is not necessarily a bad prognostic indicator that should affect the clinician's approach to management.
引用
收藏
页码:519 / 522
页数:4
相关论文
共 10 条
  • [1] Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women - The Camden study
    Chen, XH
    Scholl, TO
    Stein, TP
    [J]. DIABETES CARE, 2006, 29 (05) : 1077 - 1082
  • [2] DEFEROXAMINE THERAPY IN HIGH-FERRITIN DIABETES
    CUTLER, P
    [J]. DIABETES, 1989, 38 (10) : 1207 - 1210
  • [3] Blood letting in high-Ferrition type 2 diabetes -: Effects on vascular reactivity
    Fernández-Real, JM
    Peñarroja, G
    Castro, A
    García-Bragado, F
    López-Bermejo, A
    Ricart, W
    [J]. DIABETES CARE, 2002, 25 (12) : 2249 - 2255
  • [4] Blood letting in high-ferritin type 2 diabetes -: Effects on insulin sensitivity and β-cell function
    Fernández-Real, JM
    Peñarroja, G
    Castro, A
    García-Bragado, F
    Hernández-Aguado, D
    Ricart, W
    [J]. DIABETES, 2002, 51 (04) : 1000 - 1004
  • [5] Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years -: The data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study
    Fumeron, Frederic
    Tichet, Jean
    Pean, Franck
    Marre, Michel
    Driss, Fatti
    Grandchamp, Bernard
    Balkau, Beverley
    [J]. DIABETES CARE, 2006, 29 (09) : 2090 - 2094
  • [6] Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease
    Halle, M
    Konig, D
    Berg, A
    Keul, J
    Baumstark, MW
    [J]. ATHEROSCLEROSIS, 1997, 128 (02) : 235 - 240
  • [7] Soluble transferrin receptors and ferritin in Type 2 diabetic patients
    Hernández, C
    Lecube, A
    Carrera, A
    Simó, R
    [J]. DIABETIC MEDICINE, 2005, 22 (01) : 97 - 101
  • [8] Serum ferritin and risk of the metabolic syndrome in U.S adults
    Jehn, M
    Clark, JM
    Guallar, E
    [J]. DIABETES CARE, 2004, 27 (10) : 2422 - 2428
  • [9] Serum ferritin in healthy subjects and type 2 diabetic patients
    Kim, NH
    Oh, JH
    Choi, KM
    Kim, YH
    Baik, SH
    Choi, DS
    Kim, SJ
    [J]. YONSEI MEDICAL JOURNAL, 2000, 41 (03) : 387 - 392
  • [10] A SINGLE VISIT DIABETES COMPLICATION ASSESSMENT SERVICE - A COMPLEMENT TO DIABETES MANAGEMENT AT THE PRIMARY-CARE LEVEL
    MCGILL, M
    MOLYNEAUX, LM
    YUE, DK
    TURTLE, JR
    [J]. DIABETIC MEDICINE, 1993, 10 (04) : 366 - 370